← Back to Search

Glucagon-like peptide-1 receptor agonist

Single-arm: Semaglutide for HIV (SLIM LIVER Trial)

Phase 2
Waitlist Available
Research Sponsored by AIDS Clinical Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from pre-entry to week 24
Awards & highlights

SLIM LIVER Trial Summary

This trial will assess if a diabetes drug (Ozempic®) can reduce body fat and protect against heart & diabetes in HIV+ people. MRI will measure body fat.

Eligible Conditions
  • Prediabetes
  • HIV
  • Obesity
  • Fatty Liver
  • Insulin Resistance

SLIM LIVER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from pre-entry to week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and from pre-entry to week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change (absolute) in intra-hepatic triglyceride (IHTG) (%)

Side effects data

From 2020 Phase 4 trial • 104 Patients • NCT04189848
21%
Nausea
12%
Decreased Appetite
100%
80%
60%
40%
20%
0%
Study treatment Arm
Overall Study

SLIM LIVER Trial Design

1Treatment groups
Experimental Treatment
Group I: Single-arm: SemaglutideExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide
2019
Completed Phase 4
~5160

Find a Location

Who is running the clinical trial?

AIDS Clinical Trials GroupLead Sponsor
100 Previous Clinical Trials
73,636 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,261 Previous Clinical Trials
5,483,051 Total Patients Enrolled
Kristine Erlandson, MD, MSStudy ChairUniversity of Colorado Hospital CRS
1 Previous Clinical Trials
51 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there a substantial risk associated with the utilization of Single-arm: Semaglutide?

"Despite a lack of data regarding efficacy, evidence supporting the safety of Semaglutide in Phase 2 trials has led to Power assigning it an overall rating of 2."

Answered by AI

How many sites are hosting this experiment?

"As of now, this scientific experiment is being conducted at 7 research centres spread across Houston, Baltimore and Birmingham as well as 4 other cities. To reduce the need for travel, participants should pick a location close to them."

Answered by AI

Is the research team currently looking for new participants?

"The details hosted on clinicaltrials.gov indicate that the initial posting of this trial was October 1st 2021 and it has since been edited on December 7th 2022, thus ruling out any further recruitment. Nonetheless, 674 other trials are still actively enrolling patients at the moment."

Answered by AI

Who else is applying?

What state do they live in?
Texas
Virginia
Ohio
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
1
2
What site did they apply to?
2401 Cincinnati CRS

Why did patients apply to this trial?

~15 spots leftby Mar 2025